ArticleJournal of clinical medicine2023
Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06170918 (Half Effective Dose of Remimazolam to Prevent Cardiovascular Response to Tracheal Intubation When Combined With Fentanyl), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Half Effective Dose of Remimazolam to Prevent Cardiovascular Response to Tracheal Intubation When Combined With Fentanyl
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Emergence profiles of remimazolam-flumazenil versus propofol in pediatric general anesthesia for strabismus correction: a randomized clinical trial.BMC anesthesiology · 2025Trial
- End-of-Surgery Remimazolam Bolus Reduces Emergence Delirium in Children Undergoing Tonsillectomy and Adenoidectomy: A Randomized, Triple-Blind, Placebo-Controlled Trial.Biomedicines · 2026Article
- Remimazolam in pediatric sedation and anesthesia: current perspectives and clinical considerations.Journal of intensive care · 2026Review
- Dose Recommendation of Remimazolam Tosilate for General Anesthesia in Children and Adolescents: Synergistic Combination of PopPK and PBPK Approaches.Pharmaceutics · 2026Article
- Advantages of Remimazolam in Pediatric Anesthesia: A Narrative Review.Children (Basel, Switzerland) · 2026Review
- Remimazolam: a comprehensive review.Anaesthesiology intensive therapy · 2025Review
- Remimazolam as a Novel Anesthetic in Pediatric Procedural Sedation and Anesthesia: A Narrative Review.Cureus · 2025Review
- Optimizing Pediatric Sedation: Evaluating Remimazolam and Dexmedetomidine for Safety and Efficacy in Clinical Practice.Paediatric drugs · 2025Review
- Evaluating Remimazolam for Procedural Sedation.Current neuropharmacology · 2025Review
- Effects of remimazolam on hemodynamics in children with congenital heart disease undergoing cardiac catheterization.Frontiers in pharmacology · 2025Article
- Safety of Remimazolam in Vulnerable Populations.Drug design, development and therapy · 2025Review
- Remimazolam in pediatric ambulatory anesthesia: a critical review and clinical perspective.Frontiers in medicine · 2025Review
- Remimazolam for anesthesia and sedation in pediatric patients: a scoping review.Journal of anesthesia · 2024Article
- Remimazolam Anesthesia for a Pediatric Patient With Glutaric Aciduria Type I: A Case Report.Cureus · 2024Article
- Remimazolam and Its Place in the Current Landscape of Procedural Sedation and General Anesthesia.Journal of clinical medicine · 2024Review
- A Comprehensive Review on the Role of Melatonin's Anesthetic Applications in Pediatric Care.Cureus · 2024Review
- Clinical Application and Research Progress of Remimazolam for Pediatric Patients.Drug design, development and therapy · 2024Review
- Remimazolam in General Anesthesia: A Comprehensive Review of Its Applications and Clinical Efficacy.Drug design, development and therapy · 2024Review
- Remimazolam for Pediatric Procedural Sedation: Results of an Institutional Pilot Program.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remimazolam was first approved in 2020 as a general anesthetic for adults and still does not have pediatric labeling. Our study will be the first pilot program that administers remimazolam as an adjunct to a general endotracheal anesthetic in children. Between August 2020 and December 2022, electronic medical records were collected for all children who received remimazolam during anesthesia. The remimazolam dosing regimen was extrapolated from the adult package insert, with intravenous induction doses of 12 mg/kg/h administered until the desired effect was achieved. Subsequent infusions were given at a rate of 1-2 mg/kg/h, accompanied by intermittent boluses of 0.2 mg/kg, with all dosing adjustments made according to the anesthesiologist's clinical discretion. A total of 418 children (mean 4.6 yrs, 68.7% ASA 1 and 2) underwent surgeries which averaged 81.2 min. A total of 75.2% of patients had greater than a 20% change (increase or decrease) in MAP (lowest or highest) from baseline, and 203 (49.3%) patients had greater than a 30% change (increase or decrease) in MAP (lowest or highest) from baseline. A total of 5% received ephedrine to treat unanticipated hemodynamic variability. Discharge criteria were met within an average of 13.8 min after arrival at the post-anesthesia care unit. Remimazolam may offer the benefits of rapid recovery following general endotracheal anesthesia. The risk of hemodynamic variability which necessitates and responds to ephedrine should be anticipated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.